February 10, 2015 -
Imprivata launched Imprivata Confirm ID, a comprehensive product that enables health practitioners to electronically prescribe controlled substances.
By simplifying the adoption of regulatory requirements for EPCS, Imprivata Confirm ID enables healthcare providers to address the workflow inefficiencies and risks of fraud that stem from paper-based prescriptions.
The solution also integrates with electronic health records and provides multiple DEA-approved two-factor authentication options for prescription signing, giving providers a single, consistent e-prescribing experience for all medications.
“The industry is looking for technologies that address this inefficiency and potential for fraud while enhancing patient care,” said Imprivata president and CEO Omar Hussain. “Imprivata has worked closely with customers, leading EHR vendors, and other partners to deliver Imprivata Confirm ID, a comprehensive, integrated product that simplifies the adoption of regulatory requirements for EPCS and enables fast, secure e-prescribing of controlled substances.”
The product has various benefits including identity-proofing, supervised enrollment of providers’ approved credentials, support for multiple DEA-approved two-factor authentication modalities for prescription signing, and comprehensive auditing and reporting tools.
Imprivata Confirm ID can also be integrated directly into the e-prescribing workflows of leading EHRs and enabling providers to leverage the two-factor authentication options that meet all their prescribing workflow requirements, which ultimately increases efficiency and provider satisfaction while maintaining security.
The e-prescribing tool supports fingerprint biometric identification and one-time-password tokens, giving providers the option to use the two-factor authentication modalities that best fit their prescribing workflows.
Imprivata will host a webinar titled “Introducing Imprivata Confirm ID: Fast, Secure Signing for e-Prescribing of Controlled Substances” on February 17, 2015 at 2 p.m. EST.